HOME ABOUT US PRINT PUBLICATIONS SUBSCRIPTIONS CONTACT US RSS
 
Subscriber Sign In
 
Today@FDA
FDA Calendar
 
Archived Daily Updates
 
FDA Whistleblower
 
What do you think?
Search our 64,388-story database
Search
Renew subscription










E-mail This to a Friend | Print Format  
     
 
FDA OKs Combo Drugs for Kidney Cancer
05/16/2019
 

FDA has approved an EMD Serono and Pfizer NDA for Bavencio (avelumab) in combination with Pfizer’s Inlyta (axitinib) for the first-line treatment of patients with advanced renal cell carcinoma (RCC). This is the first FDA approval for an anti-PD-L1 therapy as part of a combination regimen for patients with advanced RCC, the companies say. Approval was based on data from the Phase 3 JAVELIN Renal 101 study (NCT02684006), in which the combination significantly improved median progression-free survival compared with sunitinib by more than five months in the intent-to-treat patient population.

 

RCC is a type of cancer where PD-L1 expression may contribute to inhibition of the immune response against the tumor, the companies say. It is also a highly vascular tumor, in which vascular endothelial growth factor plays a key role.


Post an instant comment on this report here

 
Any copying or electronic transfer without written permission is strictly prohibited and will result
in termination of service and prosecution under the federal Copyright Act.
To gain permission to copy this article log on to http://www.copyright.com.

FERDIC INCORPORATED - P.O. Box 28, Camp Hill, PA 17001 | Phone: (717)731-1426 fax:(717)731-1427 Email: info@fdaweb.com